• Clinical science
  • Clinician

Oncologic emergencies

Summary

Oncologic emergencies are a group of potentially life-threatening conditions that can manifest as a result of malignant disease and/or their treatment. These conditions include, but are not limited to, leukostasis, tumor lysis syndrome (TLS), superior vena cava (SVC) syndrome, malignant hypercalcemia, and neutropenic fever. Symptomatic patients must be rapidly assessed with early specialist intervention. Therapeutic goals in the treatment of the underlying oncologic condition (e.g., palliative care) should always be taken into account during management. TLS results from rapid destruction of tumor cells releasing intracellular components into the bloodstream that can damage the kidneys and cause potentially fatal electrolyte imbalances. Management of TLS consists of hydration, correction of electrolyte disturbances and reduction of serum uric acid to preserve kidney function. Leukostasis results from massive amounts of leukocytes that cause microcirculatory obstruction leading to organ ischemia and failure. Management of leukostasis consists of cytoreduction, hydration, and prophylaxis against TLS. SVC syndrome results from impaired blood flow from the SVC into the heart, which leads to venous congestion in the head and upper extremities. Management of SVC syndrome depends on the underlying etiology and is aimed at reducing symptoms (e.g., fluid restriction), treating complications (e.g., cerebral edema), and restoring blood flow pharmacologically, radiologically, or mechanically.

Tumor lysis syndrome

Definition [1][2]

A potentially life-threatening oncologic emergency resulting from the rapid destruction of tumor cells, which leads to a massive release of intracellular components; , e.g., potassium (K+), phosphate (PO43-), and uric acid, that can damage the kidneys and cause renal failure.

Etiology [1][2]

  • TLS most commonly occurs after initiating cytotoxic treatment in patients with hematologic malignancies (e.g., ALL, AML, or NHL).
  • Can also manifest unrelated to therapy in patients with a very high tumor burden

Pathophysiology

Think of “PUKE calcium” to remember the electrolytes affected in tumor lysis syndrome: Phosphorus, Uric acid, and potassium (K+) are Elevated; Calcium is decreased.

Clinical features [3]

Signs and symptoms are closely related to the degree of electrolyte abnormalities and acute kidney injury.

Electrolyte abnormalities in TLS can lead to seizures, cardiac arrhythmias, and sudden cardiac death. [1]

Diagnostics [1]

Consider TLS in any patient with hematological malignancies and hyperleukocytosis who have electrolyte imbalances, kidney failure, or recently initiated cytotoxic therapy.

Diagnostic criteria

Although there is no universally established classification of TLS, the Cairo-Bishop definition is widely used to help confirm the diagnosis and guide management. [2][4]

Cairo-Bishop definition of tumor lysis syndrome [3]
Laboratory TLS Clinical TLS
  • Presence of ≥ 2 of the following around the period of treatment initiation (including 3 days prior and 7 days after):
    • K+ > 6.0 mEq/L or 25% increase from baseline
    • PO43- > 4.5 mg/dL (1.45 mmol/L) or 25% increase from baseline
    • Uric acid > 8.0 mg/dL (476 micromol/L) or 25% increase from baseline
    • Corrected calcium < 7.0 mg/dL (1.75 mmol/L) or ionized Ca2+ < 4.5 mg/dL (1.12 mmol/L) or 25% decrease from baseline

Management of TLS [1][2][5][4]

  • Identify patients with established TLS and those at high risk (e.g., hematological malignancy, chemotherapy) [6]
  • Start intensive fluid therapy, uric acid reduction, and correction of electrolyte imbalances.
  • Consider notifying ICU, nephrology, and oncology early on.

Renal replacement therapy is indicated if the following complications are intractable: fluid overload, electrolyte imbalances, or hyperuricemia.

Fluid management

Hydration is the mainstay of TLS prophylaxis and treatment.

  • Low-risk patients: oral hydration, monitor fluid balance, consider IV hydration
  • Intermediate and high-risk patients, or established TLS: aggressive IV hydration (see “IV fluid therapy”)

Hydration is the most effective preventive measure.

Avoid nephrotoxic drugs (e.g., NSAIDs) and fluids with added potassium due to the risk of hyperkalemia.

Electrolyte imbalances

Monitor electrolytes regularly, as they can be also be affected by fluid therapy.

Hyperuricemia

  • Allopurinol
    • Indicated as prophylaxis in patients at low to intermediate risk
    • No additional benefit to combining with rasburicase
  • Rasburicase: recombinant uricase that catalyzes the breakdown of uric acid to allantoin
    • Indications and dosing
      • Treatment of established TLS: rasburicase infusion .
      • Prophylaxis for intermediate to high-risk patients: rasburicase infusion OR single fixed-dose rasburicase
    • Contraindications: G6PD deficiency, which can precipitate hemolytic anemia
  • Urinary alkalinization: no longer routinely recommended

Rasburicase is indicated for patients with established TLS or those at intermediate to high risk for TLS.

Acute management checklist for established TLS

Leukostasis

Definitions [8]

Etiology [8][9]

Pathophysiology

  • Very high number of leukemic blasts → increased viscosity of blood → increased risk of vascular obstruction → tissue hypoxemia and infarction clinical features of leukostasis
  • Contributing factors: endothelial activation and high metabolic activity of the dividing immature leukocytes [5]

Clinical features [9][5]

Clinical features depend on the affected system or organ. Although the lungs and the CNS are most commonly affected; , leukostasis can also cause TLS and DIC (a frequent complication of APL).

Diagnostics [9][5]

  • Leukostasis is primarily a clinical diagnosis.
  • High index of suspicionin oncologic patients with clinical features suggestive of end-organ damage
  • Hyperleukocytosis is commonly present but not mandatory for diagnosis.

Laboratory studies [9][5]

Findings are nonspecific and vary widely depending on the organ system involved and the underlying condition.

Hyperleukocytosis can lead to falsely normal platelet counts, falsely reduced PaO2, and falsely elevated potassium levels.

Imaging and additional studies [9]

Additional diagnostics should be guided by clinical symptoms and pretest probability and should not unnecessarily delay treatment.

  • Chest x-ray (if pulmonary symptoms are present): Findings include pulmonary infiltrates, pleural effusion, or normal CXR
  • CT head or MRI head (if neurological symptoms are present): Findings include ischemia, hemorrhage, masses
  • Direct fundoscopy: Findings include papilledema, retinal hemorrhages, and dilation of the retinal blood vessels. [9]
  • Bone marrow examination: required prior to initiating induction chemotherapy [9]
  • Histopathology : Microvascular occlusion by leukocyte plugs confirms the diagnosis. [5]

Leukostasis is a clinical diagnosis in leukemia patients with a markedly elevated WBC count and signs of end-organ damage (particularly the CNS and the lungs). [9]

Leukostasis is a medical emergency. Diagnostic studies should not delay treatment.

Treatment [9] [8]

General principles

  • Treatment aims to reduce the WBC count (cytoreduction) and control symptoms.
    • Induction chemotherapy is the only treatment option that improves the survival rate.
    • Leukapheresis and hydroxyurea are bridging therapies that provide rapid symptom control.
  • Admit to ICU and involve specialists early.

Cytoreduction

Individualize cytoreductive treatment regimens and involve specialists early.

  • Induction chemotherapy: treatment of choice for curative intent [9][8]
    • Regimen depends on the underlying condition.
    • Provides sustained response on WBC
    • Usually requires concurrent TLS prophylaxis
  • Leukapheresis
  • Hydroxyurea [9][5]
    • Indications
      • Bridging to induction chemotherapy (e.g., while awaiting results of diagnostic studies)
      • Contraindications for induction chemotherapy

Additional measures

Acute management checklist for leukostasis

Superior vena cava syndrome

Definition [12]

Venous congestion of the head, neck, and upper extremities resulting from impaired venous flow through the superior vena cava (SVC) to the right atrium.

Etiology [13]

Conditions that obstruct the SVC intraluminally (e.g., neoplastic invasion, thrombosis) or due to extraluminal compression (e.g., Pancoast tumors, mediastinal masses). The etiology of SVC syndrome is the basis for its classification.

Clinical features [15][12][14]

Symptoms usually progress over weeks, but rapid deterioration causing emergency presentation can occur. Evaluate patients for signs of increased ICP.

Evaluate frequently for signs of laryngeal edema, hemodynamic instability, and ↑ ICP.

Diagnostics [13][14]

  • Unstable or severely symptomatic patients : invasive venography with or without stent placement (gold-standard)
  • Stable patients
    • CT chest with CT venography: modality of choice for most patients [17]
      • Findings
        • SVC obstruction
        • Dilated collateral vessels
        • Signs of an underlying condition
    • Doppler ultrasound: initial investigation for suspected catheter-associated thrombosis [18]
      • Findings
        • Abnormal flow pattern (e.g., retrograde flow in the internal thoracic vein)
        • Visualization of a thrombus or venous incompressibility in central veins
  • Additional investigations

Management [13][20]

General principles

  • Patients with severe symptoms usually require emergency endovascular treatment. [5]
  • Definitive treatment depends on the underlying condition.
    • Malignant SVC syndrome: tumor-specific management
    • Nonmalignant SVC syndrome: directed therapy if possible, anticoagulation if thrombosis is present
  • Specialists should be involved early to provide an individualized treatment strategy.

Patients with severe or life-threatening SVC syndrome require emergency treatment (e.g., invasive venography with stent placement).

Supportive measures [13][20]

Invasive treatment

  • Stent placement: for unstable patients or patients with severe symptoms, regardless of the underlying cause
  • Surgical bypass or SVC reconstruction: individual decision [15][17]

Medical treatment [13][21][14]

Radiotherapy and chemotherapy usually require prior histologic confirmation of the underlying malignancy.

Acute management checklist for SVC syndrome

  • ABCDE assessment
  • Elevate the head.
  • Supplementary oxygen if needed
  • Check for signs of severity (e.g., cerebral edema).
  • If unstable, prepare for emergency venography and endovascular treatment.
  • Restrict fluids.
  • Consider loop diuretics.
  • Order routine laboratory studies.
  • Order first diagnostic imaging study.
    • Usually CT with CT venography
    • Consider doppler ultrasound if catheter-associated thrombosis is suspected.
  • Involve specialists early (vascular surgery, oncology, radiation oncology, interventional radiology).
  • 1. Howard SC, Jones DP, Pui C-H. The Tumor Lysis Syndrome. N Engl J Med. 2011; 364(19): pp. 1844–1854. doi: 10.1056/nejmra0904569.
  • 2. Jones GL, Will A, Jackson GH, Webb NJA, Rule S. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015; 169(5): pp. 661–671. doi: 10.1111/bjh.13403.
  • 3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127(1): pp. 3–11. doi: 10.1111/j.1365-2141.2004.05094.x.
  • 4. Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. J Clin Oncol. 2008; 26(16): pp. 2767–2778. doi: 10.1200/jco.2007.15.0177.
  • 5. Halfdanarson TR, Hogan WJ, Madsen BE. Emergencies in Hematology and Oncology. Mayo Clin Proc. 2017; 92(4): pp. 609–641. doi: 10.1016/j.mayocp.2017.02.008.
  • 6. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010; 149(4): pp. 578–586. doi: 10.1111/j.1365-2141.2010.08143.x.
  • 7. McBride, PharmD, MS, BCPS A, Trifilio, RPh S, Baxter, MNSc, APN-BC, AOCNP N, K. Gregory, MD T, C. Howard, MD, MS S. Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies. J Adv Pract Oncol. 2017; 8(7). doi: 10.6004/jadpro.2017.8.7.4.
  • 8. Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev. Hematol. 2016; 10(2): pp. 147–154. doi: 10.1080/17474086.2017.1270754.
  • 9. Alaa M. Ali, Aibek E. Mirrakhimov, Camille N. Abboud, Amanda F. Cashen. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest. Hematol Oncol. 2016; 34(2): pp. 69–78. doi: 10.1002/hon.2292.
  • 10. Shaz BH, MD BH, Hillyer CD, MD CD, Gil MR. Transfusion Medicine and Hemostasis. Elsevier Science; 2019: p. 1050.
  • 11. Hölig K, Moog R. Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia. Transfus Med Hemother. 2012; 39(4): pp. 241–245. doi: 10.1159/000341805.
  • 12. Wilson LD, Detterbeck FC, Yahalom J. Superior Vena Cava Syndrome with Malignant Causes. N Engl J Med. 2007; 356(18): pp. 1862–1869. doi: 10.1056/nejmcp067190.
  • 13. Straka C, Ying J, Kong F-M, Willey CD, Kaminski J, Kim DWN. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. SpringerPlus. 2016; 5(1). doi: 10.1186/s40064-016-1900-7.
  • 14. Lepper PM, Ott SR, Hoppe H, et al. Superior Vena Cava Syndrome in Thoracic Malignancies. Respir Care. 2011; 56(5): pp. 653–666. doi: 10.4187/respcare.00947.
  • 15. Yu JB, Wilson LD, Detterbeck FC. Superior Vena Cava Syndrome—A Proposed Classification System and Algorithm for Management. J Thorac Oncol. 2008; 3(8): pp. 811–814. doi: 10.1097/jto.0b013e3181804791.
  • 16. McCurdy MT, Shanholtz CB. Oncologic emergencies. Crit Care Med. 2012; 40(7): pp. 2212–2222. doi: 10.1097/ccm.0b013e31824e1865.
  • 17. Kalra M, Sen I, Gloviczki P. Endovenous and Operative Treatment of Superior Vena Cava Syndrome. Surg Clin North Am. 2018; 98(2): pp. 321–335. doi: 10.1016/j.suc.2017.11.013.
  • 18. Baarslag H-J, van Beek EJR, Koopman MMW, Reekers JA. Prospective Study of Color Duplex Ultrasonography Compared with Contrast Venography in Patients Suspected of Having Deep Venous Thrombosis of the Upper Extremities. Ann Intern Med. 2002; 136(12): p. 865. doi: 10.7326/0003-4819-136-12-200206180-00007.
  • 19. Zimmerman S, Davis M. Rapid Fire: Superior Vena Cava Syndrome. Emerg Med Clin North Am. 2018; 36(3): pp. 577–584. doi: 10.1016/j.emc.2018.04.011.
  • 20. Skoch BM, Sinclair CT. Management of Urgent Medical Conditions at the End of Life. Med Clin North Am. 2020; 104(3): pp. 525–538. doi: 10.1016/j.mcna.2019.12.006.
  • 21. Wan JF, Bezjak A. Superior Vena Cava Syndrome. Hematol Oncol Clin North Am. 2010; 24(3): pp. 501–513. doi: 10.1016/j.hoc.2010.03.003.
  • 22. Rachapalli V, Boucher L-M. Superior Vena Cava Syndrome: Role of the Interventionalist. Can Assoc Radiol J. 2014; 65(2): pp. 168–176. doi: 10.1016/j.carj.2012.09.003.
  • Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician. J Emerg Med. 2019; 57(1): pp. 36–42. doi: 10.1016/j.jemermed.2019.03.043.
  • Jim Yeung SC, Escalante C. Oncologic Emergencies. In: Hong WK, Bast RJ, Hait WN, et al., eds. Cancer Medicine 8. PMPH- USA; 2010.
  • Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J. Thromb. Haemost. 2011; 9(2): pp. 312–319. doi: 10.1111/j.1538-7836.2010.04126.x.
  • Liu M, Wang G, Li Y, et al. Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology. 2020; 12: p. 175883592090754. doi: 10.1177/1758835920907540.
  • Stanford W, Doty DB. The Role of Venography and Surgery in the Management of Patients with Superior Vena Cava Obstruction. Ann Thorac Surg. 1986; 41(2): pp. 158–163. doi: 10.1016/s0003-4975(10)62659-8.
  • Pham HP, Schwartz J. How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. Transfusion (Paris). 2015; 55(10): pp. 2306–2311. doi: 10.1111/trf.13210.
  • Rice TW, Rodriguez RM, Light RW. The Superior Vena Cava Syndrome. Medicine. 2006; 85(1): pp. 37–42. doi: 10.1097/01.md.0000198474.99876.f0.
  • Long B, Warix JR, Koyfman A. Controversies in Management of Hyperkalemia. J Emerg Med. 2018; 55(2): pp. 192–205. doi: 10.1016/j.jemermed.2018.04.004.
last updated 10/13/2020
{{uncollapseSections(['1X12C20', '-X1D0f0', 'rX1fz20', 'V11Gff0'])}}